Efficacy, safety and tolerability of formula-based unilateral vs bilateral electroconvulsive therapy in the treatment of major depression: A randomized open label controlled trial

2021 ◽  
Vol 133 ◽  
pp. 52-59
Author(s):  
Monika Dominiak ◽  
Anna Z. Antosik-Wójcińska ◽  
Zuzanna Goetz ◽  
Olga Sikorska ◽  
Bogdan Stefanowski ◽  
...  
Keyword(s):  
Major Depression ◽  
Electroconvulsive Therapy ◽  
Controlled Trial ◽  
Open Label

Efficacy and Tolerability of Mirtazapine versus Paroxetine in the Treatment of Major Depressive Disorder

2012 ◽  
Vol 4 ◽  
pp. CMT.S7632
Author(s):  
Alexandre González Rodriguez ◽  
Cristóbal Gastó Ferrer ◽  
Victor Navarro Odriozola
Keyword(s):  
Clinical Trial ◽  
Major Depressive Disorder ◽  
Major Depression ◽  
Depressive Disorder ◽  
Controlled Trial ◽  
Assessment Tools ◽  
Publication Type ◽  
Open Label ◽  
Major Depressive ◽  
Randomized Controlled

Objective To compare the efficacy and tolerability of paroxetine and mirtazapine in the treatment of major depression. Data sources Searches were conducted to identify studies through Medline (1980-2011), PsycInfo (1980-2011) and PubMed databases up to June 2011. The searches were not restricted to publication type or clinical trial design. Study Selection A clinical trial was included if it described a trial of paroxetine versus mirtazapine in patients with major depression, based on the research evidence of reviews. Data Abstraction Three assessors analyzed the quality of the trials and extracted study design data, trial features, efficacy and toler-ability assessment tools, discontinuation reasons for both antidepressants and remitter and responder rates. Results We included six randomized controlled trials, one open-label, randomized controlled trial and four systematic reviews and metaanalysis. Rates of remission and response between mirtazapine and paroxetine were compared: at the beginning (1-2 weeks) there were statistically significant differences in mirtazapine treated patients, but these were not found at the end of assessment period (6-8 weeks). Discontinuation rates between the two drugs showed no differences, with an adverse event profile characteristic of each drug. Conclusions Mirtazapine and paroxetine were equally effective and well-tolerated in major depressive disorder. Differences in effectiveness were only observed in the first or second week of treatment when mirtazapine showed earlier onset of action.

scholarly journals Comparison of the target-controlled infusion and the manual infusion of propofol anesthesia during electroconvulsive therapy: an open-label randomized controlled trial

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Meng-Ling Hsieh ◽  
Yen-Ting Lu ◽  
Chih-Chung Lin ◽  
Chin-Pang Lee
Keyword(s):  
Electroconvulsive Therapy ◽  
Cognitive Assessment ◽  
Controlled Trial ◽  
Open Label ◽  
Established Method ◽  
Early Course ◽  
Randomized Controlled ◽  
Target Controlled Infusion ◽  
Before And After ◽  
Higher Doses

Abstract Background Target-controlled infusion (TCI) of propofol is a well-established method of procedural sedation and has been used in Japan for anesthesia during electroconvulsive therapy (ECT). However, the usefulness of the TCI of propofol for ECT has yet to be determined. This study aimed to compare the TCI and manual infusion (MI) of propofol anesthesia during ECT. Methods A total of forty psychiatric inpatients receiving bitemporal ECT were enrolled in the present study and randomized into the TCI group (N = 20) and the MI group (N = 20). Clinical Global Impression (CGI) and Montreal Cognitive Assessment (MoCA) scores were measured before and after ECT. The clinical outcomes, anesthesia-related variables, and ECT-related variables were compared between the two groups. Generalized estimating equations (GEEs) were used to model the comparison throughout the course of ECT. Results A total of 36 subjects completed the present study, with 18 subjects in each group. Both the groups didn’t significantly differ in the post-ECT changes in CGI and MoCA scores. However, concerning MoCA scores after 6 treatments of ECT, the MI group had improvement while the TCI group had deterioration. Compared with the MI group, the TCI group had higher doses of propofol, and longer procedural and recovery time. The TCI group seemed to have more robust seizures in the early course of ECT but less robust seizures in the later course of ECT compared with the MI group. Conclusions The present study does not support the use of TCI of propofol for anesthesia of ECT. Trial registration (ClinicalTrials.gov): NCT03863925. Registered March 5, 2019 - Retrospectively registered.

Impact of Temperature on Injection-Related Pain Caused by Subcutaneous Administration of Ustekinumab: A Three-arm Crossover Open-label Randomized Controlled Trial

2017 ◽  
Vol 1 (3) ◽  
pp. 117-127
Author(s):  
Yasaman Mansouri ◽  
Yasmin Amir ◽  
Michelle Min ◽  
Raveena Khanna ◽  
Ruiqi Huang ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Subcutaneous Administration ◽  
Open Label ◽  
Post Dose ◽  
Subcutaneous Injections ◽  
Pain Scores ◽  
Observational Cohort ◽  
Vas Scores ◽  
Pre Treatment ◽  
To Receive

Background: Adherence to subcutaneous biologic agents for the treatment of psoriasis can be negatively influenced by injection pain.Objective: To explore the differences in injection site pain when patients are pre-treated with heat or cold, versus no pre-treatment prior to administration of a subcutaneous biologic agent.Methods: In an observational cohort study, patients receiving subcutaneous injections of ustekinumab were randomly assigned to receive pretreatment with ice, heat, or no intervention over three visits. Post-dose, patients rated pain on a 100 mm visual analogue scale (VAS).Results: There was an increase in the VAS score for both heat (2.51, P=0.30) and ice (3.33, P=0.16), compared to no intervention. No differences were found between the two intervention groups (-0.83, P=0.73). On average, females had the same VAS scores with ice compared to that of no intervention (-0.12, P=0.97) and a non–significant decrease of 3.29 points (P=0.38) with heat. Males had increased pain scores by 5.65 points (P=0.07) with ice and by 6.39 points (P=0.04) with heat.Limitations: Pain is a subjective measurement and objective quantification is difficult.Conclusions: On average, neither heat nor cold application reliably reduced pain. Our results do not support the application of heat or cold prior to ustekinumab injection.

Sign in / Sign up

Export Citation Format

Share Document